Abstract
Forty-one patients with advanced breast cancer were given carboplatin and vinorelbine as second-line therapy. Overall objective response rate was 46% (95% confidence interval 26-56%). Myelotoxicity was the most frequently observed toxic effect; grade III-IV leucopenia occurred in 46% of the patients. Our regimen is active as second-line chemotherapy for advanced breast cancer and warrants further evaluation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Iaffaioli, R., Tortoriello, A., Facchini, G. et al. A phase II study of carboplatin and vinorelbine as second-line treatment for advanced breast cancer. Br J Cancer 72, 1256–1258 (1995). https://doi.org/10.1038/bjc.1995.496
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.496
This article is cited by
-
Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000–02 phase II study
Clinical and Translational Oncology (2011)
